DDR2 (N456S)
Sign in to save this workspaceDDR2 · Variant type: point · HGVS: p.N456S
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ponatinib | 100.0% | 0.0% | 78.23 |
| 2 | Tivozanib | 100.0% | 0.0% | 92.42 |
| 3 | Nintedanib | 100.0% | 0.0% | 90.23 |
| 4 | Dasatinib | 100.0% | 0.0% | 87.97 |
| 5 | Ripretinib | 99.9% | 0.1% | 92.95 |
| 6 | Repotrectinib | 99.8% | 0.2% | 84.21 |
| 7 | Nilotinib | 99.1% | 0.9% | 96.49 |
| 8 | Cabozantinib | 98.1% | 1.9% | 92.73 |
| 9 | Sorafenib | 97.8% | 2.2% | 96.72 |
| 10 | Regorafenib | 97.8% | 2.2% | 95.99 |
| 11 | Erdafitinib | 97.7% | 2.3% | 95.71 |
| 12 | Bosutinib | 97.7% | 2.3% | 87.22 |
| 13 | Pralsetinib | 97.1% | 2.9% | 93.43 |
| 14 | Selpercatinib | 96.5% | 3.5% | 96.72 |
| 15 | Vandetanib | 95.9% | 4.1% | 95.74 |
| 16 | Lenvatinib | 94.9% | 5.1% | 97.74 |
| 17 | Entrectinib | 92.5% | 7.5% | 93.69 |
| 18 | Fedratinib | 90.8% | 9.2% | 96.21 |
| 19 | Imatinib | 90.6% | 9.4% | 99.00 |
| 20 | Pazopanib | 89.4% | 10.6% | 97.49 |
| 21 | Apatinib | 88.5% | 11.5% | 97.73 |
| 22 | Umbralisib | 87.1% | 12.9% | 98.74 |
| 23 | Canertinib | 86.7% | 13.3% | 96.49 |
| 24 | Dabrafenib | 85.7% | 14.3% | 94.74 |
| 25 | Gilteritinib | 81.8% | 18.2% | 88.97 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ponatinib | 100.0% | 100.0% | +0.0% |
| Tivozanib | 100.0% | 99.3% | +0.7% |
| Nintedanib | 100.0% | 100.0% | +0.0% |
| Dasatinib | 100.0% | 99.6% | +0.4% |
| Ripretinib | 99.9% | 94.8% | +5.1% |
| Repotrectinib | 99.8% | 98.3% | +1.5% |
| Nilotinib | 99.1% | 99.7% | -0.6% |
| Cabozantinib | 98.1% | 100.0% | -1.9% |
| Sorafenib | 97.8% | 96.3% | +1.5% |
| Regorafenib | 97.8% | 97.6% | +0.2% |
| Erdafitinib | 97.7% | 93.5% | +4.2% |
| Bosutinib | 97.7% | 97.6% | +0.1% |
| Pralsetinib | 97.1% | 95.9% | +1.2% |
| Selpercatinib | 96.5% | 92.2% | +4.3% |
| Vandetanib | 95.9% | 98.5% | -2.7% |
| Lenvatinib | 94.9% | 94.3% | +0.6% |
| Entrectinib | 92.5% | — | — |
| Fedratinib | 90.8% | — | — |
| Imatinib | 90.6% | — | — |
| Pazopanib | 89.4% | — | — |
| Apatinib | 88.5% | — | — |
| Umbralisib | 87.1% | — | — |
| Canertinib | 86.7% | — | — |
| Dabrafenib | 85.7% | 95.4% | -9.7% |
| Gilteritinib | 81.8% | 96.7% | -14.9% |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_lung | Lung | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 35.3ms